Accelerating the development of generic drugs to cope with the rise of major diseases

"With the incidence rate and mortality rate of major diseases showing a trend of continuous rise and younger in China, the direction of" new drug creation "should be changed as soon as possible, and thus the development of" generic drugs "will be accelerated Liu Gexin, deputy to the National People's Congress and chairman of Sichuan Kelun Industrial Group Co., Ltd., said that "generic medicine" is a huge social public wealth in the world, with the advantage of low price It has good economic and social benefits in improving the level of medical service, reducing medical expenditure, maintaining public health and other aspects Compared with the original research drugs, the development of "generic drugs" requires less investment, short cycle and quick results, which is in line with the grim situation of major diseases rising and high medical costs in China Liu Chuangxin suggested that, on the one hand, China should gradually integrate the quality requirements and supervision of "generic drugs" with the international standards With high standards and scientific management standards for drug approval and review, the existing domestic drug research teams should carry out more scientific and professional drug research, produce high-quality "generic drugs" and strengthen the national pharmaceutical industry On the other hand, we need to further reform the market access mechanism of our country, and establish a rapid evaluation and reasonable pricing system for high-quality "generic drugs" and excellent innovative drugs.